Managing Hot Flushes and Night Sweats

The medication is commonly used across domains where short-term symptom management is appropriate for symptoms related to heightened physiological activity, such as vasomotor symptoms. The medicine may assist with symptom clusters that may become intense or disruptive, including hot flushes and night sweats. This application is relevant in scenarios where additional management of discomfort is required, offering symptomatic relief that helps patients cope more steadily with symptom fluctuations.

---

Alleviating Other Menopause-Related Discomfort

Oestrodose 0.06% is applied across domains where additional symptomatic support is needed, assisting with symptoms that interfere with daily functioning, such as changes in mood, irritability, and temporary fatigue. The medication is commonly used across conditions presenting with systemic or localized discomfort, assisting with symptoms that interfere with daily functioning, which may include vasomotor symptoms and localized discomfort related to inflammatory or irritative states. This provides support that helps ease the overall symptom burden.

“It helps address symptom clusters that may become intense or disruptive.”

---

Quick Facts on Therapeutic Domains

Quick Fact: Symptoms Addressed
The medication is applied in contexts involving symptomatic discomfort associated with heightened physiological activity and inflammatory or irritative states where short-term symptomatic assistance is appropriate.

Who Can and Cannot Use Oestrodose 0.06%?

Oestrodose 0.06% (estradiol gel) is officially approved for use in postmenopausal women seeking systemic estrogen replacement. Eligibility is governed by strict regulatory rules detailing populations who must not use the medicine.

Absolute Contraindications

Use is strictly prohibited if there is a known, suspected, or history of breast cancer or other estrogen-dependent malignant tumors. Oestrodose is also contraindicated in individuals with active or a history of thromboembolic disease (including DVT, PE, stroke, or MI), known thrombophilic disorders, or known liver impairment or disease. Absolute exclusions also include undiagnosed abnormal genital bleeding and untreated endometrial hyperplasia.

Age and Conditional Restrictions

The gel is not indicated for the pediatric population due to a lack of established safety and efficacy data. For women 65 years of age and older, ancillary study data notes an increased risk of probable dementia. Use is contraindicated during pregnancy and not recommended during lactation. A critical conditional rule for women with an intact uterus requires the addition of a progestogen to limit the risk of endometrial proliferation.

Interactions with other medicines and products

Interactions with Oral Medications and Herbals

Estradiol, the active ingredient in this product, is partly metabolized by the CYP3A4 enzyme system in the liver. Products that induce this enzyme, such as certain anti-convulsants (phenobarbital, carbamazepine), anti-infectives (rifampin), and herbal preparations like St. John’s Wort (Hypericum perforatum), may reduce estradiol plasma concentrations. This may decrease the therapeutic effect or cause changes in the uterine bleeding profile. Conversely, CYP3A4 inhibitors may increase estradiol levels.

Interactions with Specific Treatments

Caution is required when co-administering estradiol with certain Hepatitis C Virus (HCV) combination drug regimens (e.g., ombitasvir/paritaprevir/ritonavir with or without dasabuvir, and glecaprevir/pibrentasvir). While significant liver enzyme (ALT) elevations were more frequent with another estrogen, caution is still warranted due to limited data with estradiol.

Interactions with Topical Products

Since this is a transdermal gel, its absorption can be altered by other products applied to the skin. Strong skin cleansers or detergents, products with high alcoholic content (like astringents or sunscreens), and keratolytics (e.g., salicylic acid) can remove the drug from the skin surface, reducing its effect. Furthermore, applying moisturizing lotion one hour after application has been shown to increase estradiol absorption. Avoid the use of concomitant skin medications that alter skin production.

Oestrodose 0.06% contains estradiol, which is absorbed transdermally into the systemic circulation, bypassing first-pass hepatic metabolism. Estradiol functions as an agonist at both the estrogen receptor alpha (ERalpha) and estrogen receptor beta (ERbeta).

Following passive diffusion into target cells, estradiol binds to these intracellular nuclear receptors. This ligand-receptor complex subsequently translocates to the cell nucleus, where it interacts directly with specific DNA sequences known as estrogen response elements (EREs) located in the promoter regions of target genes.

This interaction modulates the transcription rate of these genes, leading to an alteration in the synthesis of specific cellular proteins. This transcriptional regulation ultimately influences the proliferation, differentiation, and functional activity of various estrogen-responsive tissues, including bone, the central nervous system, and the reproductive tract. At the systemic level, increased circulating estradiol levels modulate the hypothalamic-pituitary axis through a negative feedback loop, suppressing the pituitary secretion of gonadotropins, specifically luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

How to Use Oestrodose 0.06%: Administration Guidelines

Oestrodose 0.06% (estradiol 0.06% hydroalcoholic gel) is administered topically using a metered-dose pump for systemic estrogen replacement. The dosage and administration are defined by established standards, specifying the route, frequency, and required procedural steps to ensure proper delivery.

---

Dosing and Administration Schedules

The gel is applied once daily at approximately the same time each day. Dosing recommendations vary depending on the specific protocol. The starting dose is generally 1.25 g of gel (one pump actuation), delivering 0.75 mg of estradiol daily. In some cases, the starting dose is 2.5 g of gel (two pump actuations), with the maximum dose set at 5.0 g (four pump actuations) daily. The dose may be adjusted after one month if initial response is insufficient.

Regimen Type	Description (Based on Uterine Status)
Continuous	Estrogen (gel) administered daily, typically for women who have had a hysterectomy.
Continuous Sequential	Estrogen (gel) administered daily, with a progestogen added for 12 days per month for women with an intact uterus.

---

Application Protocol and Constraints

The gel is intended for application on clean, dry, intact skin, usually on a large area such as the arm from the wrist to the shoulder, or the inner thigh. Before initial use, the pump must be primed by depressing it fully multiple times to ensure the correct dose is dispensed. After application, the gel should be allowed to dry for 5 minutes before dressing. To prevent unintended transfer of the active substance, skin contact with others at the application site must be avoided for at least one hour after use. In the event of a forgotten dose, the missed dose is typically applied immediately unless it is closer than 12 hours to the next scheduled dose, in which case the missed dose should be skipped. The medication is not indicated for use in children.

Research evidence / Overview of Studies for Oestrodose 0.06%

The following summary describes the nature of the research available for estradiol 0.06% transdermal gel, focusing on the types of studies conducted, the outcomes they measured, and areas where research remains limited, without providing any medical or clinical guidance.

---

Evidence for Use in Moderate to Severe Vasomotor Symptoms

Research exploring how symptoms change over time has focused on short-term Randomized Controlled Trials (RCTs). These studies were used in a research context involving fluctuating or unstable symptoms, such as the hot flushes and night sweats experienced by postmenopausal women. The main outcomes measured were related to physical discomfort, specifically the frequency and intensity of these episodes, using patient-reported outcomes describing perceived discomfort.

Studies monitored patterns in the measured count and the intensity of symptoms reported by the observed populations over periods typically lasting 12 weeks. The results apply only to the populations studied, and the follow-up durations were limited to a few months. The long-term outcomes and durability of effects for this specific gel formulation are not well characterized by these core trials.

---

Research on Systemic Hormonal Levels and Delivery

Research examined the gel's delivery method through Pharmacokinetic (PK) Studies. These studies were conducted to understand how the active ingredient, estradiol, is absorbed and processed by the body after being applied to the skin. The main outcomes monitored were serum estradiol levels in the blood, measuring how high and how consistently the hormone concentration was maintained over defined time intervals.

These studies explored how the transdermal system achieved systemic replacement and described the characteristic pattern of bypassing first-pass liver metabolism. The data show patterns related to maintaining steady hormonal concentrations. However, the long-term impact of the specific PK profile is not well established by studies focused solely on the gel formulation; this information is primarily inferred from the broader evidence landscape of general hormone therapy.

Common questions about Oestrodose 0.06% (FAQ)

Q: How long does it typically take to notice the expected effects of Oestrodose 0.06%?

Official information derived from studies suggests continuing the treatment for at least three months to allow for assessment of symptom changes. This timeframe allows for the body to reach a steady state of hormone levels.

Q: Can a partner be exposed to the medicine if contact occurs after application?

The active ingredient may be transferred to others through direct skin contact with the application site before the gel is completely absorbed. Regulatory guidance specifies that skin contact with others should be avoided for at least one hour after application to prevent unintended exposure.

Q: Are there specific instructions about washing hands after applying Oestrodose 0.06%?

Regulatory instructions explicitly state that the user should wash their hands thoroughly immediately after applying the gel. This procedural step is intended to help prevent the accidental transfer of the medication to other areas of the body or to other people.

Q: What are the official recommendations regarding Oestrodose 0.06% and smoking?

Smoking is identified in official documents as a pre-existing risk factor for increased risk of serious cardiovascular events, such as blood clots or stroke, when using estrogen therapy. This information is noted as an important safety factor in regulatory documentation.

Q: Is Oestrodose 0.06% considered a long-term treatment?

Official guidance states that hormone replacement therapy should be used at the lowest effective dose for the shortest duration consistent with treatment goals. The need for continued treatment is generally reevaluated periodically by a prescribing professional.

Q: Are there different brand names for the same formulation as Oestrodose 0.06%?

Yes, the same 0.06% estradiol transdermal gel formulation is marketed under different brand names in various regions. Examples of other brand names for this product include EstroGel and Oestrogel.

Q: Is Oestrodose 0.06% an effective option for preventing bone density loss?

Official therapeutic indications state that the product is indicated for the prevention of osteoporosis (bone density loss) in postmenopausal women. This indication applies specifically to individuals who are at high risk of future fractures and cannot use other approved medications for prevention.

Q: How does Oestrodose 0.06% compare to patches or pills for similar purposes?

Oestrodose 0.06% is a transdermal gel applied to the skin. This delivery method allows the estradiol to enter the bloodstream directly, bypassing the liver's first-pass metabolism, which is descriptive of the transdermal delivery method.

Q: Does Oestrodose 0.06% have a strong scent?

Official descriptions note the gel is clear, colorless, and has an odour of alcohol when first applied, which is due to its hydroalcoholic base. However, it is generally described as having no noticeable scent once the alcohol evaporates and the gel is dry.

Q: Can Oestrodose 0.06% cause weight changes?

Regulatory safety information lists both weight gain and weight loss as possible effects that have been associated with the use of estrogen therapy.

Q: Is hair loss a reported side effect of Oestrodose 0.06%?

Hair loss is a reported side effect that has been associated with the use of estrogen therapy, as documented in official safety information.

Q: Can Oestrodose 0.06% be used if someone has a history of breast cancer in the family?

Official documents state the product is strictly contraindicated (prohibited) for individuals with a known, past, or suspected personal history of breast cancer. A first-degree family history is noted as a condition requiring careful consideration and monitoring.

Q: Are there any known issues with Oestrodose 0.06% and sun exposure?

Estrogen therapy may increase the risk of developing chloasma, which appears as brown patches on the skin. This condition is known to be worsened by exposure to sunlight or ultraviolet (UV) radiation, which is an important safety consideration in regulatory warnings.

Q: Is it normal to feel a change in mood after starting Oestrodose 0.06%?

Mood changes, including feelings of low mood or depression, are listed as potential effects associated with the use of estrogen therapy. This is often noted to occur during the first few months of treatment.

Q: Is Oestrodose 0.06% associated with changes to cholesterol levels?

Estrogen therapy may be associated with changes in certain lipid (fat) and cholesterol levels in the blood. Official information indicates that high cholesterol (Hyperlipidemia) is a known pre-existing risk factor that is often considered a factor for close monitoring.

Q: Does Oestrodose 0.06% affect liver function according to official sources?

Official documents state that the product is strictly contraindicated for use in individuals with acute liver disease or impaired liver function. It is worth noting that the transdermal application method bypasses first-pass liver metabolism.

Q: Does Oestrodose 0.06% interact with thyroid medications?

Estrogen therapy can increase thyroid binding globulin (TBG), which affects how thyroid hormones circulate. Official guidance suggests that this may lead to a need for dose adjustments and monitoring of thyroid levels.

Q: Is the pump mechanism designed to dispense a precise amount?

Yes, the pump is specifically a metered-dose system. It is engineered to dispense a precise and measured amount of gel with each full pump actuation, which is intended to ensure the consistent and accurate delivery of the prescribed dose of estradiol.

Q: Can Oestrodose 0.06% be used during travel to different time zones?

Official instructions recommend applying the gel once daily at approximately the same time each day to maintain consistent hormone levels. This regular schedule is aimed at helping to ensure consistent hormone levels.

Q: Is Oestrodose 0.06% known to affect sleep patterns?

Sleep disturbances are not directly listed as a common side effect of the gel itself. However, the treatment is licensed for symptoms of menopause, such as vasomotor symptoms (including night sweats), which are known to be disruptive to sleep.

Q: Does Oestrodose 0.06% contain alcohol or other preservatives?

Yes, the gel is a hydroalcoholic gel and contains Ethanol (alcohol) as a required excipient. The full list of excipients, which includes purified water, triethanolamine, and carbomer 934P, is available in the official Summary of Product Characteristics (SmPC).

Q: Is Oestrodose 0.06% licensed for use in treating symptoms beyond hot flashes?

Yes, official therapeutic indications state that the product is also licensed for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, in addition to moderate to severe vasomotor symptoms (hot flashes).

Q: Does applying Oestrodose 0.06% to different skin areas change the effect?

Official administration guidelines specify application only to the arm (wrist to shoulder) or inner thigh for consistent absorption. Use on other body areas, such as the face or chest, is not part of the documented instructions and could affect the consistency of hormone delivery.

Q: What is the shelf life of an unopened tube of Oestrodose 0.06%?

The product's shelf life is indicated by the expiry date (Exp.) printed on the outer packaging and the metered-dose pump. This date is determined by stability testing and applies to the product while unopened.

Q: How quickly does Oestrodose 0.06% dry after application?

Official instructions advise allowing the gel to dry for 5 minutes before dressing or covering the application area. This time is necessary to ensure proper absorption and to prevent the medication from transferring to clothing or other surfaces.

How to Store and Dispose of Oestrodose 0.06% (Estradiol Gel)

Oestrodose 0.06% must be stored according to specific regulatory conditions to maintain its stability and prevent fire hazards or accidental exposure. The estradiol gel must be stored at a Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).

Storage and Handling

• Flammability Warning: Due to its alcohol base, the gel is flammable. It must be kept away from heat, sparks, open flames, and all ignition sources; no smoking is permitted in the storage area.
• Protection: The container must be kept tightly closed and stored out of the sight and reach of children.

Disposal

• Priming Disposal: Unused gel from the initial pump priming step must be safely discarded by rinsing it down the sink or placing it in the household trash.
• General Disposal: Expired or unused final product containers must be disposed of in accordance with local regulations and should not be thrown into wastewater.